PflegeTab - A tablet-based approach for improving the level of well-being and quality of life in people affected by dementia

A Tablet-based intervention for Nursing Home Residents suffering from Alzheimer’s Disease and Related Disorders: A cluster-randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN98947160

Enrollment

240

Registered

2016-09-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease and related disorders (dementia) Mental and Behavioural Disorders Alzheimers disease and related disorders (dementia)

Interventions

Participants are randomised at nursing home level (cluster-randomisation) to one of two groups. Intervention group: Over a period of 8 weeks, experimental group participants will enga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Nursing home residents diagnosed with dementia (MMST < 24) 2. Informed consent of participant (and legal guardian)

Exclusion criteria

Exclusion criteria: 1. Other chronic psychiatric conditions 2. Resident for less than 4 weeks

Design outcomes

Primary

Measure	Time frame
Engagement is measured using the Adult Education Survey (AES) at baseline and after 8 weeks.	—

Secondary

Measure	Time frame
1. Dementia-related quality of life is measured using the QOL-AD questionnaire (patient) and the Qualidem scale (caregiver) at baseline and after 8 weeks 2. Behavioural symptoms are measured using the Neuropsychiatric Inventory – Nursing Home Version (NPI-NH) questionnaire at baseline and after 8 weeks 3. Cognition is measured using the Mini-Mental State Examination (MMSE) and the Alters-Konzentrations-Test (AKT) at baseline and after 8 weeks 4. Autonomy/iADL is measured using the Barthel Index and the Functional Assessment Staging Test (FAST) questionnaire at baseline and after 8 weeks 5. Depression is measured using the Geriatric Depression Scale (GDS) at baseline and after 8 weeks 6. Engagement is measured using behavioural data (number of solved tasks, number of mistouches, number of errors, etc.) assessed via tablet during each activation session (intervention group only) 7. Intensive longitudinal assessments are undertaken using a short version of the Qualidem scale administered before and after every single activation session in both intervention and control group	—

Measure

Time frame

1. Dementia-related quality of life is measured using the QOL-AD questionnaire (patient) and the Qualidem scale (caregiver) at baseline and after 8 weeks 2. Behavioural symptoms are measured using the Neuropsychiatric Inventory – Nursing Home Version (NPI-NH) questionnaire at baseline and after 8 weeks 3. Cognition is measured using the Mini-Mental State Examination (MMSE) and the Alters-Konzentrations-Test (AKT) at baseline and after 8 weeks 4. Autonomy/iADL is measured using the Barthel Index and the Functional Assessment Staging Test (FAST) questionnaire at baseline and after 8 weeks 5. Depression is measured using the Geriatric Depression Scale (GDS) at baseline and after 8 weeks 6. Engagement is measured using behavioural data (number of solved tasks, number of mistouches, number of errors, etc.) assessed via tablet during each activation session (intervention group only) 7. Intensive longitudinal assessments are undertaken using a short version of the Qualidem scale administered before and after every single activation session in both intervention and control group

—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 18, 2026